Belize vs Papua New Guinea: Access to anti-retroviral drugs, female
Belize
51.0%
in 2024
Papua New Guinea
51.0%
in 2024
Belize rank
118th
Papua New Guinea rank
118th
Access to anti-retroviral drugs, female over time
- Belize
- Papua New Guinea
How they compare
Belize currently reports 51.0% against 51.0% in Papua New Guinea, a difference of 0.0%.
The two have swapped places 2 times across 25 shared years of data; in 2000 it was Papua New Guinea ahead.
Belize ranks 118th and Papua New Guinea ranks 118th of 141 countries.
Belize has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Belize | Papua New Guinea | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 9.1% | 3.8% | 5.3% | Belize |
| 2010s | 37.9% | 30.4% | 7.5% | Belize |
| 2020s | 47.8% | 46.2% | 1.6% | Belize |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, female, Belize or Papua New Guinea?
- Belize, at 51.0% against 51.0% in Papua New Guinea as of 2024.
- What is the difference in access to anti-retroviral drugs, female between Belize and Papua New Guinea?
- 0.0%, with Belize ahead.
- How many years of comparable data are there for Belize and Papua New Guinea?
- 25 years are reported by both, from 2000 to 2024.
- How do Belize and Papua New Guinea rank globally for access to anti-retroviral drugs, female?
- Belize ranks 118th and Papua New Guinea ranks 118th of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, female (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult females living with HIV who are receiving antiretroviral therapy.